Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...123124125126127128129130131132133...858859»
  • ||||||||||  Journal:  Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib. (Pubmed Central) -  Oct 24, 2023   
    Also, the imprinting factor (IF) analysis was performed on selected drug substances having structural similarities to SOR and the relative IF values of regorafenib, leflunomide, teriflunomide, nilotinib, axitinib, and dasatinib indicated the selectivity of the developed sensor for SOR...This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  RegoMel: A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (clinicaltrials.gov) -  Oct 24, 2023   
    P2,  N=48, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | N=16 --> 48 | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion, Trial completion date, Trial primary completion date:  COLLIDE: Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab (clinicaltrials.gov) -  Oct 23, 2023   
    P=N/A,  N=16, Completed, 
    Initiation date: Dec 2022 --> Dec 2023 Recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion, Trial completion date, Trial primary completion date:  COMPETE: Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab (clinicaltrials.gov) -  Oct 23, 2023   
    P=N/A,  N=16, Completed, 
    Recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023 Recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Oct 2023
  • ||||||||||  brazikumab (AMG 139) / AstraZeneca
    Trial termination:  INTREPID OLE: Open-label Extension Study of Brazikumab in Crohn's Disease (clinicaltrials.gov) -  Oct 23, 2023   
    P3,  N=18, Terminated, 
    Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Dec 2025 --> Apr 2024 Active, not recruiting --> Terminated; Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
  • ||||||||||  tapotoclax (AMG 176) / Amgen
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia (clinicaltrials.gov) -  Oct 23, 2023   
    P1,  N=120, Recruiting, 
    Active, not recruiting --> Terminated; Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Dec 2025
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Trial initiation date, HEOR, Real-world evidence, Real-world:  ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) -  Oct 23, 2023   
    P=N/A,  N=200, Recruiting, 
    Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Dec 2025 Initiation date: Dec 2022 --> Jun 2022
  • ||||||||||  Review, Journal:  THE HEART FAILURE KNIGHTS. (Pubmed Central) -  Oct 23, 2023   
    Cardiac myosin stimulator, omecamtiv mecarbil, has shown efficacy in HFrEF, lowering HF related events or cardiovascular death, while the two inhibitors, mavacamten and aficamten have been shown to reduce hypercontractility and left ventricular outflow obstruction improving functional capacity in randomized trials targeting hypertrophic cardiomyopathy. These agents are the prototypes of active pipelines promising to deliver an array of molecules against HF in the near future.
  • ||||||||||  Camzyos (mavacamten) / BMS, omecamtiv mecarbil (AMG 423) / Amgen, Servier, Simdax (levosimendan IV) / AbbVie
    Review, Journal:  Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review. (Pubmed Central) -  Oct 23, 2023   
    The review also evaluates the efficacy of the novel treatments in comparison to traditional medications such as digoxin. Finally, we seek to provide insight and guidance to clinicians and researchers in the management of HF patients.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Systemic Therapy for Melanoma: ASCO Guideline Update. (Pubmed Central) -  Oct 22, 2023   
    Talimogene laherparepvec is no longer recommended as an option for patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. Ipilimumab- and ipilimumab-containing regimens are no longer recommended for patients with BRAF-mutated disease after progression on other therapies.This full update incorporates the new recommendations for uveal melanoma published in the 2022 Rapid Recommendation Update.Additional information is available at www.asco.org/melanoma-guidelines.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer. (Pubmed Central) -  Oct 22, 2023   
    Both clinical PFS and OS in the concomitant PPI group were consistently poor in patients receiving endocrine-sensitive and endocrine-resistant treatment. These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.
  • ||||||||||  Review, Journal:  Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies. (Pubmed Central) -  Oct 22, 2023   
    These compounds block the translation of messenger RNA (mRNA) into apo(a), a key structural component of Lp(a), thereby substantially reducing Lp(a) synthesis in the liver. The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid-lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, raloxifene hydrochloride / Generic mfg., alendronate / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: a meta-analysis. (Pubmed Central) -  Oct 22, 2023   
    In patients at stage 5 CKD and undergoing hemodialysis, alendronate and raloxifene increased lumbar spine BMD...These medications may increase the incidence of adverse events and their safety needs to be further evaluated. Therefore, we cannot draw a definitive conclusion about the efficacy and safety of osteoporosis medications in the above group of patients.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
    Journal, Metastases:  Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. (Pubmed Central) -  Oct 22, 2023   
    Lastly, data from a cohort of 52 patients indicated that patients with HR-positive/HER2-negative MBC who progressed on palbociclib-containing regimens can exhibit a meaningful overall clinical benefit from abemaciclib-based therapy when administered after palbociclib. These findings provide the rationale for clinical trials evaluating the benefit of abemaciclib treatment following progression on a prior CDK4/6i.
  • ||||||||||  Review, Journal:  Treatment with Biologic Drugs in Pediatric Beh (Pubmed Central) -  Oct 22, 2023   
    Both group of biologic treatments appeared to be effective and have an acceptable safety profile in pediatric BD. However, controlled studies are required for analyzing indications for biologic treatments in pediatric BD.
  • ||||||||||  Journal, Metastases:  Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. (Pubmed Central) -  Oct 22, 2023   
    On avacopan, the patient was able to discontinue mycophenolate mofetil (MMF) while maintaining remission. To our knowledge, this is the first reported case of hallucinations caused by ribociclib; notably, it shows that symptoms may develop in the early stage of treatment.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  New insights in the pathophysiology, epidemiology and response to treatment of osteoporotic vertebral fractures. (Pubmed Central) -  Oct 22, 2023   
    Endocrinologists should be aware of the high likelihood of osteoporotic VFs in patients with endocrine diseases. Though licensed treatments are able to substantially reduce the occurrence of VFs in patients with osteoporosis, the vast majority of recent or ongoing randomized controlled trials in the VF area focus on advanced invasive therapy of the fracture itself.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
    Journal, Metastases:  Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. (Pubmed Central) -  Oct 22, 2023   
    Since the liver biopsy was toxic hepatitis, it was thought that other drugs used by the patient might cause this toxicity, and a significant decrease was observed in liver values after discontinuation of denosumab. Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature.
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  Postural Orthostatic Tachycardia Syndrome as a Sequela of COVID-19. (Pubmed Central) -  Oct 22, 2023   
    For example, ivabradine or ?-blockers in combination with compression stockings and increasing salt and fluid intake has shown potential...Considering our limited understanding of Post-COVID-19 POTS, further research on topics such as its natural history, pathophysiological mechanisms, and ideal treatment is warranted. This review evaluates the current literature available on the associations between COVID-19 and POTS, possible mechanisms, patient assessment, treatments, and future directions to improving our understanding of Post-COVID-19 POTS.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Denosumab Therapy in Cherubism. (Pubmed Central) -  Oct 22, 2023   
    Close follow-up is needed to maintain appropriate electrolyte levels. The present case demonstrates the achievement of symptomatic control with denosumab in a child with severe refractory cherubism.